Effects of Remote-based Resistance Training on Cardiometabolic Risk Factors, Cognitive Function, and Quality of Life in Adults Living With Alzheimer's Disease and/or Related Dementias

Sponsor
Drexel University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05004558
Collaborator
Mercy Health (Other)
36
1
9

Study Details

Study Description

Brief Summary

The investigators aim to study the effects of a 24-week remote-based resistance exercise training program on cardiovascular disease risk factors, cognitive function, and quality of life in older adults living with mild cognitive impairment or Alzheimer's Disease and/or a related dementia. Data for this study will be collected at the beginning, middle, and end of the resistance training program. Participants of this study will receive a baseline health-fitness assessment at the beginning of the study. Measurements of resting blood pressure, fasting blood glucose and lipids, waist and hip circumferences, height and weight, cognitive function and quality of life will be collected at the health-fitness assessment. Participants will then receive supervised remote-based resistance exercise training with Therabands, 3 days per week for 12 weeks before receiving a second 12-week health-fitness assessment in the middle of the intervention. Participants will then receive 12 additional weeks of supervised remote-based resistance exercise training with Therabands, 3 days per week for 12 weeks before receiving a third 24-week health fitness assessment at the end of the study.

Detailed Description

The investigators aim to study the effects of a 24-week remote-based resistance exercise training program on cardiovascular disease risk factors, cognitive function, and quality of life in older adults living with mild cognitive impairment or Alzheimer's Disease and/or a related dementia. Data for this study will be collected at the beginning, middle, and end of the resistance training program. Measurements of resting blood pressure will be collected with an automated blood pressure monitor. Fasting blood glucose and lipids will be retrieved from the electronic medical record or from a finger stick. Waist and hip circumferences will be collected with a tape measure. Height and weight will be collected with a physician scale. Cognitive function and quality of life will be collected from interviews using the Montreal Cognitive Assessment and Short-Form (36) Health Survey. All data collected from this study will be de-identified using the "Safe-Harbor" method, which minimizes exposure of personal health information by providing each participant with a unique participant-ID and only providing access to those who are listed and approved for access privileges. Data collected for this study will also be stored on an encrypted and password- protected hard drive, and data analyzed will be performed with the Statistical Package for the Social Sciences using analyses of covariance.

When participants are enrolled in the study, he/she will be grouped on the basis of their cognitive function status from the Montreal Cognitive Assessment. All participants will then receive supervised remote-based resistance exercise training with Therabands, 3 days per week for 24 weeks. The risks of participating in exercise programs are minimal. Some of the possible risks of participating in resistance exercise include becoming tired and/or experiencing delayed onset muscle soreness, leg cramping, or muscle strain from performing resistance exercise. There are several benefits from engaging in resistance exercise programs. Participants of this study will receive health-fitness assessment at the beginning, middle, and end of the study, and as such, will benefit from being made aware of their cardiovascular disease risk factors, cognitive function, and quality of life. Other possible benefits from participation in the resistance exercise program may include improvements in muscular size and strength and/or activities of daily living.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
36 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Effects of a 24-week Remote-based Resistance Training Program on Parameters of the Metabolic Syndrome, Cognitive Function, and Quality of Life in Older Adults Living With Mild Cognitive Impairment and Alzheimer's Disease and/or a Related Dementia
Anticipated Study Start Date :
Sep 1, 2021
Anticipated Primary Completion Date :
Mar 1, 2022
Anticipated Study Completion Date :
Jun 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: Remote-based Resistance Exercise Training

All participants enrolled in the trial will receive supervised remote-based resistance exercise training. The exercises will be performed with the use of Therabands and will include 8-10 exercises performed for 1 set of 15 repetitions, performed 3 days per week for 24 weeks.

Other: Remote-based Resistance Exercise Training
All participants enrolled in the trial will receive supervised remote-based resistance exercise training. The exercises will be performed with the use of Therabands and will include 8-10 exercises performed for 1 set of 15 repetitions, performed 3 days per week for 24 weeks.

Outcome Measures

Primary Outcome Measures

  1. Resting systolic blood pressure, measured in mmHg from 0 and above with higher numbers indicating higher blood pressure [Baseline]

    Resting systolic blood pressure will be measured with an automated blood pressure device, measured in mmHg from 0 and above with higher numbers indicating higher blood pressure

  2. Resting systolic blood pressure, measured in mmHg from 0 and above with higher numbers indicating higher blood pressure [12 weeks]

    Resting systolic blood pressure will be measured with an automated blood pressure device, measured in mmHg from 0 and above with higher numbers indicating higher blood pressure

  3. Resting systolic blood pressure, measured in mmHg from 0 and above with higher numbers indicating higher blood pressure [24 weeks]

    Resting systolic blood pressure will be measured with an automated blood pressure device, measured in mmHg from 0 and above with higher numbers indicating higher blood pressure

  4. Resting diastolic blood pressure, measured in mmHg from 0 and above with higher numbers indicating higher blood pressure [Baseline]

    Resting diastolic blood pressure will be measured with an automated blood pressure device, measured in mmHg from 0 and above with higher numbers indicating higher blood pressure

  5. Resting diastolic blood pressure, measured in mmHg from 0 and above with higher numbers indicating higher blood pressure [12 weeks]

    Resting diastolic blood pressure will be measured with an automated blood pressure device, measured in mmHg from 0 and above with higher numbers indicating higher blood pressure

  6. Resting diastolic blood pressure, measured in mmHg from 0 and above with higher numbers indicating higher blood pressure [24 weeks]

    Resting diastolic blood pressure will be measured with an automated blood pressure device, measured in mmHg from 0 and above with higher numbers indicating higher blood pressure

  7. Height, red with a stadiometer in inches from 0 and above with higher numbers indicating taller height [Baseline]

    Height will be measured with a stadiometer in inches from 0 and above with higher numbers indicating taller height

  8. Height, red with a stadiometer in inches from 0 and above with higher numbers indicating taller height [12 weeks]

    Height will be measured with a stadiometer in inches from 0 and above with higher numbers indicating taller height

  9. Height, red with a stadiometer in inches from 0 and above with higher numbers indicating taller height [24 weeks]

    Height will be measured with a stadiometer in inches from 0 and above with higher numbers indicating taller height

  10. Weight, ured with a physican scale in pounds from 0 and above with higher numbers indicating heavier weight [Baseline]

    Weight will be measured with a physican scale in pounds from 0 and above with higher numbers indicating heavier weight

  11. Weight, ured with a physican scale in pounds from 0 and above with higher numbers indicating heavier weight [12 weeks]

    Weight will be measured with a physican scale in pounds from 0 and above with higher numbers indicating heavier weight

  12. Weight, ured with a physican scale in pounds from 0 and above with higher numbers indicating heavier weight [24 weeks]

    Weight will be measured with a physican scale in pounds from 0 and above with higher numbers indicating heavier weight

  13. Body mass index, measured in meters squared, from 0 and above wiith larger values indicating a higher body mass index [Baseline]

    Body mass index will be measured as the weight measured in kilograms divided by the height measured in meters squared, from 0 and above wiith larger values indicating a higher body mass index

  14. Body mass index, measured in meters squared, from 0 and above wiith larger values indicating a higher body mass index [12 weeks]

    Body mass index will be measured as the weight measured in kilograms divided by the height measured in meters squared, from 0 and above wiith larger values indicating a higher body mass index

  15. Body mass index, measured in meters squared, from 0 and above wiith larger values indicating a higher body mass index [24 weeks]

    Body mass index will be measured as the weight measured in kilograms divided by the height measured in meters squared, from 0 and above wiith larger values indicating a higher body mass index

  16. Waist circumference, red in inches with a Gulick tape measure from 0 and above with higher numbers indicating a larger waist circumference [Baseline]

    Waist circumference will be measured in inches with a Gulick tape measure from 0 and above with higher numbers indicating a larger waist circumference

  17. Waist circumference, red in inches with a Gulick tape measure from 0 and above with higher numbers indicating a larger waist circumference [12 weeks]

    Waist circumference will be measured in inches with a Gulick tape measure from 0 and above with higher numbers indicating a larger waist circumference

  18. Waist circumference, red in inches with a Gulick tape measure from 0 and above with higher numbers indicating a larger waist circumference [24 weeks]

    Waist circumference will be measured in inches with a Gulick tape measure from 0 and above with higher numbers indicating a larger waist circumference

  19. Hip circumference, sured in inches with a Gulick tape measure from 0 and above with higher numbers indicating a larger waist circumference [Baseline]

    Hip circumference will be measured in inches with a Gulick tape measure from 0 and above with higher numbers indicating a larger waist circumference

  20. Hip circumference, sured in inches with a Gulick tape measure from 0 and above with higher numbers indicating a larger waist circumference [12 weeks]

    Hip circumference will be measured in inches with a Gulick tape measure from 0 and above with higher numbers indicating a larger waist circumference

  21. Hip circumference, sured in inches with a Gulick tape measure from 0 and above with higher numbers indicating a larger waist circumference [24 weeks]

    Hip circumference will be measured in inches with a Gulick tape measure from 0 and above with higher numbers indicating a larger waist circumference

  22. Blood glucose, measured in mg/dL from 0 and above with larger values indicating a higher blood glucose concentration [Baseline]

    Blood glucose will be measured with a Cholestech LDX analyzer via finger sticking, measured in mg/dL from 0 and above with larger values indicating a higher blood glucose concentration

  23. Blood glucose, measured in mg/dL from 0 and above with larger values indicating a higher blood glucose concentration [12 weeks]

    Blood glucose will be measured with a Cholestech LDX analyzer via finger sticking, measured in mg/dL from 0 and above with larger values indicating a higher blood glucose concentration

  24. Blood glucose, measured in mg/dL from 0 and above with larger values indicating a higher blood glucose concentration [24 weeks]

    Blood glucose will be measured with a Cholestech LDX analyzer via finger sticking, measured in mg/dL from 0 and above with larger values indicating a higher blood glucose concentration

  25. High density lipoprotein cholesterol, ed in mg/dL from 0 and above with larger values indicating a higher high density lipoprotein concentrations, a desirable finding [Baseline]

    High density lipoprotein cholesterol will be measured with a Cholestech LDX analyzer via finger sticking, measured in mg/dL from 0 and above with larger values indicating a higher high density lipoprotein concentrations, a desirable finding

  26. High density lipoprotein cholesterol, ed in mg/dL from 0 and above with larger values indicating a higher high density lipoprotein concentrations, a desirable finding [12 weeks]

    High density lipoprotein cholesterol will be measured with a Cholestech LDX analyzer via finger sticking, measured in mg/dL from 0 and above with larger values indicating a higher high density lipoprotein concentrations, a desirable finding

  27. High density lipoprotein cholesterol, ed in mg/dL from 0 and above with larger values indicating a higher high density lipoprotein concentrations, a desirable finding [24 weeks]

    High density lipoprotein cholesterol will be measured with a Cholestech LDX analyzer via finger sticking, measured in mg/dL from 0 and above with larger values indicating a higher high density lipoprotein concentrations, a desirable finding

  28. Low density lipoprotein cholesterol, measured in mg/dL from 0 and above with larger values indicating a higher low density lipoprotein concentrations, an undesirable finding [Baseline]

    Low density lipoprotein cholesterol will be measured with a Cholestech LDX analyzer via finger sticking, measured in mg/dL from 0 and above with larger values indicating a higher low density lipoprotein concentrations, an undesirable finding

  29. Low density lipoprotein cholesterol, measured in mg/dL from 0 and above with larger values indicating a higher low density lipoprotein concentrations, an undesirable finding [12 weeks]

    Low density lipoprotein cholesterol will be measured with a Cholestech LDX analyzer via finger sticking, measured in mg/dL from 0 and above with larger values indicating a higher low density lipoprotein concentrations, an undesirable finding

  30. Low density lipoprotein cholesterol, measured in mg/dL from 0 and above with larger values indicating a higher low density lipoprotein concentrations, an undesirable finding [24 weeks]

    Low density lipoprotein cholesterol will be measured with a Cholestech LDX analyzer via finger sticking, measured in mg/dL from 0 and above with larger values indicating a higher low density lipoprotein concentrations, an undesirable finding

  31. Triglycerides, measured in mg/dL from 0 and above with larger values indicating a higher triglyceride concentrations, an undesirable finding [Baseline]

    Triglycerides will be measured with a Cholestech LDX analyzer via finger sticking, measured in mg/dL from 0 and above with larger values indicating a higher triglyceride concentrations, an undesirable finding

  32. Triglycerides, measured in mg/dL from 0 and above with larger values indicating a higher triglyceride concentrations, an undesirable finding [12 weeks]

    Triglycerides will be measured with a Cholestech LDX analyzer via finger sticking, measured in mg/dL from 0 and above with larger values indicating a higher triglyceride concentrations, an undesirable finding

  33. Triglycerides, measured in mg/dL from 0 and above with larger values indicating a higher triglyceride concentrations, an undesirable finding [24 weeks]

    Triglycerides will be measured with a Cholestech LDX analyzer via finger sticking, measured in mg/dL from 0 and above with larger values indicating a higher triglyceride concentrations, an undesirable finding

  34. Total cholesterol, measured in mg/dL from 0 and above with larger values indicating a higher total cholesterol concentrations, an undesirable finding [Baseline]

    Total cholesterol will be measured with a Cholestech LDX analyzer via finger sticking, measured in mg/dL from 0 and above with larger values indicating a higher total cholesterol concentrations, an undesirable finding

  35. Total cholesterol, measured in mg/dL from 0 and above with larger values indicating a higher total cholesterol concentrations, an undesirable finding [12 weeks]

    Total cholesterol will be measured with a Cholestech LDX analyzer via finger sticking, measured in mg/dL from 0 and above with larger values indicating a higher total cholesterol concentrations, an undesirable finding

  36. Total cholesterol, measured in mg/dL from 0 and above with larger values indicating a higher total cholesterol concentrations, an undesirable finding [24 weeks]

    Total cholesterol will be measured with a Cholestech LDX analyzer via finger sticking, measured in mg/dL from 0 and above with larger values indicating a higher total cholesterol concentrations, an undesirable finding

Secondary Outcome Measures

  1. Cognitive Function as Measured by the Montreal Cognitive Assessment [Baseline]

    Cognitive function will be assessed with the Montreal Cognitive Assessment Screen, measured from 0 to 30 with higher scores indicating better cognitive function

  2. Cognitive Function as Measured by the Montreal Cognitive Assessment [12 weeks]

    Cognitive function will be assessed with the Montreal Cognitive Assessment Screen, measured from 0 to 30 with higher scores indicating better cognitive function

  3. Cognitive Function as Measured by the Montreal Cognitive Assessment [24 weeks]

    Cognitive function will be assessed with the Montreal Cognitive Assessment Screen, measured from 0 to 30 with higher scores indicating better cognitive function

  4. Quality of Life as measured by the Short-Form (36) Health Survey [Baseline]

    Quality of life will be assessed with the Short-Form (36) Health Survey, measured from 0 to 100 with higher scores indicating better quality of life

  5. Quality of Life as measured by the Short-Form (36) Health Survey [12 weeks]

    Quality of life will be assessed with the Short-Form (36) Health Survey, measured from 0 to 100 with higher scores indicating better quality of life

  6. Quality of Life as measured by the Short-Form (36) Health Survey [24 weeks]

    Quality of life will be assessed with the Short-Form (36) Health Survey, measured from 0 to 100 with higher scores indicating better quality of life

Eligibility Criteria

Criteria

Ages Eligible for Study:
55 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • 55 years of age or older

  • Sedentary or not meeting the current physical activity guidelines of at least 150 minutes of moderate-to-vigorous physical activity per week

  • Live with or have a primary in-home caregiver or legal representative who can be physically present during the remote-based exercise sessions

  • Have access to a computer, tablet, or smartphone with internet and webcam access for the HIPAA compliant virtual Zoom meetings.

Exclusion Criteria:
  • Younger than 55 years of age

  • Accustomed to resistance exercise training during the previous year

  • Live with known or suggestive uncontrolled cardiovascular, metabolic, and/or renal disease

  • Live with musculoskeletal injury that precludes their ability to perform remote-based, resistance exercise training

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Drexel University
  • Mercy Health

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Michael Bruneau, Assistant Professor, Drexel University
ClinicalTrials.gov Identifier:
NCT05004558
Other Study ID Numbers:
  • THMA 2021-21
First Posted:
Aug 13, 2021
Last Update Posted:
Aug 13, 2021
Last Verified:
Aug 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 13, 2021